RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.

@article{Anton2012RMP02MTN006AP,
  title={RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.},
  author={Peter A Anton and Ross D. Cranston and Angela Dm Kashuba and Craig W Hendrix and Namandj{\'e} N Bumpus and Nicola Richardson-Harman and Julie Marie Elliott and Laura Janocko and Elena Khanukhova and Robert Dennis and William G. Cumberland and Chuan Ju and Alex Carballo-Dieguez and Christine K. Mauck and Ian Mcgowan},
  journal={AIDS research and human retroviruses},
  year={2012},
  volume={28 11},
  pages={
          1412-21
        }
}
This study was designed to assess the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic (PD) responses to rectal administration of tenofovir (TFV) 1% vaginally formulated gel and oral tenofovir disoproxil fumarate (TDF). This study was designed as a phase 1, randomized, two-site (United States), double-blind, placebo-controlled study of sexually abstinent men and women. Eighteen participants received a single 300-mg exposure of oral TDF and were then randomized 2:1 to receive a… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 69 CITATIONS, ESTIMATED 45% COVERAGE

Rectal pre-exposure prophylaxis (PrEP).

  • Antiviral research
  • 2013
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

and Drug Administration: FDA approval of Truvada for a PrEP indication: Label information

U. S. Foo
  • Available at http://www accessdata fda gov/scripts/cder/drugsatfda/ index cfm?fuseaction = Search Label_ApprovalHistory#apphist
  • 2012